A 36-year-old cisgender woman with HIV and hepatitis C virus (HCV) who meets the criteria for the simplified HCV treatment approach is scheduled to start a 12-week course of sofosbuvir-velpatasvir. Her baseline HCV RNA level, which was checked 2 weeks prior, is 3.2 million copies/mL. She does not have cirrhosis, is immune to hepatitis B virus (HBV), and is not pregnant. She is taking bictegravir-tenofovir alafenamide-emtricitabine for treatment of HIV. She has excellent adherence with her HIV medication and is anticipated to have excellent adherence with HCV treatment.